undamentalytics Newsletter
Sign in

Uniqure N.V. (QURE) stock

Add to watchlist

Add holding +

NASDAQ: QURE Nasdaq Biotechnology Next results ~November 4, 2026

Uniqure N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Uniqure N.V. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.

Uniqure N.V. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 12 selling0 purchases and 57 sales by directors and officers, last 12 monthsInsider trades
  • Funds174 adding, 107 cuttingOf 59 active managers that changed their stake, 34 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 51% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Uniqure N.V.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 143% and a beta of 0.3 against the S&P 500.
  • Insiders selling. 12 insiders sold $22M of stock over the past 365 days and none bought (90% under pre-set trading plans).
  • Heavily shorted. 12.8% of the shares available to trade are sold short (2.5 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$1.07 against an average estimate of -$0.71: missed by 51.2%
Share reaction
+15.1% in the first session after the results on July 29, 2026, against +0.1% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$0.82

Uniqure's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-7.5%
  • 1 week+6.1%
  • 1 month-2.1%
  • This year-4.0%
  • 1 year-66.1%
  • 5 years-36.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
July 29, 2026
Next results (est.)
November 9, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Uniqure N.V. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $5m and EPS of −$0.82 (range −$1.05 to −$0.66) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.44 −17% $21m +55%
Next −$2.64 +23% $96m +356%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +9.5% on 90 days ago. In the last 30 days, 2 analysts raised Uniqure N.V.'s forecast and 4 cut it.

Consensus EPS forecast Uniqure N.V., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.14 Current fiscal year, 60 days ago: −$3.43 Current fiscal year, 30 days ago: −$3.43 Current fiscal year, 7 days ago: −$3.44 Current fiscal year, Now: −$3.44 −$3.44 Next fiscal year, 90 days ago: −$2.50 Next fiscal year, 60 days ago: −$2.59 Next fiscal year, 30 days ago: −$2.63 Next fiscal year, 7 days ago: −$2.64 Next fiscal year, Now: −$2.64 −$2.64

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.14−$2.50
60 days ago −$3.43−$2.59
30 days ago −$3.43−$2.63
7 days ago −$3.44−$2.64
Now −$3.44−$2.64

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.71 −$1.07 −51.2%
Mar 2026 −$0.75 −$0.73 +3.3%
Dec 2025 −$0.78 −$0.47 +39.2%
Sept 2025 −$0.75 −$1.19 −59.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

13 analysts, Oct 2026
Buy1185%
Hold215%
Sell00%

Monthly trend

  1. Oct 2026110213
  2. Sep 202629112
  3. Aug 202629112
  4. Jul 202629112

Counts of recommendations published by analysts covering Uniqure N.V., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
12.8%
of tradable shares
Days to cover
2.55
at average volume
Short interest, 1 month
−12%
to October 15, 2026
Held by institutions
98%
of shares
Held by insiders
1.3%
of shares
Employees
221
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
QURE−43%+9%−70%+161%+36%−4%
Industry peers (median)−35%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
QURE25%33%8%50%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
QURE−52%−39%−76%−55%−72%−68%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 95% from June 21, 2019 to July 8, 2024. Getting back needed a 2074% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$9.03 – $51.05
From 52-week high
−55.0%
vs 50-day average
−32.5%
vs 200-day average
−22.6%
Volatility (1 year)
143%
Beta vs S&P 500
0.35

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±13.4%
After a week
9 up, 3 down
typical move ±14.4%
After a month
9 up, 3 down
typical move ±20.4%
Results releasedNext dayS&P 500 next day5 days21 days
July 29, 2026 +15.1% +0.1% +20.7% +35.2%
May 5, 2026 +10.3% +2.2% +40.7% +35.3%
March 2, 2026 −42.2% −0.8% +15.1% +4.6%
November 10, 2025 +11.0% +1.8% +9.1% −27.5%
July 29, 2025 −3.5% −0.4% −6.5% +5.1%
May 9, 2025 +7.3% +3.2% +11.8% +33.4%
February 27, 2025 +12.7% −0.1% +7.2% +6.9%
November 5, 2024 +28.8% +3.7% +21.0% +18.5%
August 1, 2024 −4.6% −3.3% −5.6% −23.6%
May 7, 2024 +3.6% +0.1% +4.0% +12.5%
February 28, 2024 −14.8% +0.2% −23.3% −23.0%
November 7, 2023 +6.5% +0.4% +8.3% +19.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $15.9M 99.0% ▲ 57.2%
Collaborative Revenue $164,000 1.0% ▼ 98.5%

From Uniqure N.V.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$3.1B
Institutions reporting
254
Shares held vs prior quarter
▲ 10.7%
Positions opened / closed
89 / 48

Top buyers and sellers, Q2 2026: 174 institutions bought and 107 sold ; the biggest buyer was Jpmorgan Chase & Co (+2.0M shares) and the biggest seller Aberdeen Group PLC (−2.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Avoro Capital Advisors LLC $310M 6.7M 10.1% ▲ 12.9%
Jpmorgan Chase & Co $231M 4.9M 7.5% ▲ 71.6%
RTW Investments, LP $182M 3.9M 5.9% ▲ 52.4%
State Street Corp $134M 2.9M 4.4% ▲ 28.5%
Aberdeen Group PLC $131M 2.8M 4.3% ▼ 46.3%
Blackrock, Inc. $86.5M 1.9M 2.8% ▲ 8.3%
Orbimed Advisors LLC $83.3M 1.8M 2.7% ▼ 15.4%
Jane Street Group, LLC $74.2M 1.6M 2.4% ▲ 153.2%
Jennison Associates LLC $71.9M 1.6M 2.3% ▲ 26.6%
Boxer Capital Management, LLC $69.2M 1.5M 2.3% ▲ 127.1%
Goldman Sachs Group Inc $68M 1.5M 2.2% ▲ 16.8%
Two Sigma Investments, LP $67.3M 1.5M 2.2% ▼ 45.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Uniqure N.V.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $22.1M 57 trades by 12 insiders · 90% under pre-set plans
Net ▼ $22.1M net selling
Insider Date Trade Shares Price Value
Kapusta Matthew C CEO, Managing Director July 2, 2026 Sell pre-set plan 9,200 $44.43 $408,756
Kapusta Matthew C CEO, Managing Director July 2, 2026 Sell pre-set plan 4,282 $45.43 $194,531
Kapusta Matthew C CEO, Managing Director July 2, 2026 Sell pre-set plan 7,600 $45.89 $348,764
Kaye Jack Director June 30, 2026 Sell pre-set plan 4,107 $46.49 $190,934
Kaye Jack Director June 30, 2026 Sell pre-set plan 17,060 $46.43 $792,096
Abi-Saab Walid Chief Medical Officer June 30, 2026 Sell pre-set plan 10,000 $46.46 $464,600
Abi-Saab Walid Chief Medical Officer June 30, 2026 Sell pre-set plan 20,000 $46.40 $928,000
Abi-Saab Walid Chief Medical Officer June 26, 2026 Sell 1,434 $46.86 $67,197
Kapusta Matthew C CEO, Managing Director June 25, 2026 Sell pre-set plan 28,716 $50.02 $1.4M
Kapusta Matthew C CEO, Managing Director June 24, 2026 Sell pre-set plan 6,696 $50.00 $334,800
Kapusta Matthew C CEO, Managing Director June 18, 2026 Sell pre-set plan 4,656 $50.00 $232,800
Kapusta Matthew C CEO, Managing Director June 18, 2026 Sell pre-set plan 37,015 $50.00 $1.9M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • July 29, 2026
  • May 5, 2026
  • March 2, 2026
  • November 10, 2025
  • July 29, 2025
  • May 9, 2025

Recent SEC filings

Data status

When each part of this page on Uniqure N.V. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Uniqure N.V. in brief

What does Uniqure N.V. do?
Uniqure N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Uniqure N.V.'s stock ticker?
Uniqure N.V. trades under the ticker QURE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Uniqure N.V.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Avoro Capital Advisors LLC, Jpmorgan Chase & Co and RTW Investments, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Uniqure N.V. stock?
Over the last 12 months, Uniqure N.V.'s directors and officers reported 0 open-market purchases and 57 sales on Form 4. The insider trading page charts every trade.
When is Uniqure N.V.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Uniqure N.V. announces its own schedule.